Discovery of Highly Active Derivatives of Daptomycin by Assessing the Effect of Amino Acid Substitutions at Positions 8 and 11 on a Daptomycin Analogue
- 22 March 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 8 (4) , 778-789
Abstract
Daptomycin is an important antibiotic used for treating serious infections caused by Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci. Establishing structure–activity relationships of daptomycin is important for developing new daptomycin-based antibiotics with expanded clinical applications and for tackling the ever-increasing problem of antimicrobial resistance. Toward this end, Dap-K6-E12-W13, an active analogue of daptomycin in which the uncommon amino acids in daptomycin are replaced with their common counterparts, was used as a model system for studying the effect of amino acid variation at positions 8 and 11 on in vitro biological activity against a model organism, Bacillus subtilis, and calcium-dependent insertion into model membranes. None of the new peptides were more active than Dap-K6-E12-W13; however, substitution at positions 8 and/or 11 with cationic residues resulted in little or no loss of activity, and some of these analogues were able to insert into model membranes at lower calcium ion concentrations than the parent peptide. Incorporation of these cationic residues into positions 8 and/or 11 of daptomycin itself yielded some derivatives that exhibited lower minimum inhibitory concentrations than daptomycin against B. subtilis 1046 as well as comparable and sometimes superior activity against clinical isolates of MRSA.Keywords
Funding Information
- Natural Sciences and Engineering Research Council of Canada (04233-2017, 250265-2013)
- Government of Ontario
This publication has 42 references indexed in Scilit:
- Oligomerization of daptomycin on membranesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- Production of novel lipopeptide antibiotics related to A54145 by Streptomyces fradiae mutants blocked in biosynthesis of modified amino acids and assignment of lptJ, lptK and lptL gene functionsThe Journal of Antibiotics, 2010
- Genetically Engineered Lipopeptide Antibiotics Related to A54145 and Daptomycin with Improved PropertiesAntimicrobial Agents and Chemotherapy, 2010
- Daptomycin: pharmacology and clinical useExpert Opinion on Pharmacotherapy, 2010
- Agar and broth dilution methods to determine the minimal inhibitory concentration (MIC) of antimicrobial substancesNature Protocols, 2008
- Combinatorial biosynthesis of novel antibiotics related to daptomycinProceedings of the National Academy of Sciences, 2006
- Chemoenzymatic Design of Acidic Lipopeptide Hybrids: New Insights into the Structure−Activity Relationship of Daptomycin and A54145Biochemistry, 2006
- Synthesis and Derivatization of Daptomycin: A Chemoenzymatic Route to Acidic Lipopeptide AntibioticsJournal of the American Chemical Society, 2004
- Structural Transitions as Determinants of the Action of the Calcium-Dependent Antibiotic DaptomycinChemistry & Biology, 2004
- Chemo- and Regioselective Peptide Cyclization Triggered by the N-Terminal Fatty Acid Chain Length: The Recombinant Cyclase of the Calcium-Dependent Antibiotic from Streptomyces coelicolorBiochemistry, 2004